乳腺X线与MRI筛查的相对时序对乳腺筛查性能评估的影响
基于乳腺癌症监测联盟2005至2017年8260次筛查性乳腺X线摄影,配对±90天内的MRI定义为联合筛查、91至270天定义为交替筛查。联合筛查中作为单一联合检测的癌检出率为每1000次13.1、敏感度96.2%,高于单独乳腺X线(6.8、48.1%)和单独MRI(12.3、79.7%)。交替筛查中采用截断随访后乳腺X线癌检出率由3.6降至0、MRI敏感度由75.0%升至86.7%。
要点
- 联合筛查作为单一检测的敏感度96.2%,高于单独乳腺X线48.1%和单独MRI79.7%。
- 联合筛查作为单一检测的癌检出率为每1000次13.1,单独乳腺X线6.8、单独MRI12.3。
- 交替筛查采用截断随访后,乳腺X线癌检出率由每1000次3.6降至0,敏感度无法计算(分母=0)。
核心结论
- 更新审计方法以考虑联合与交替筛查的时序安排,并处理重叠随访期带来的结局归因问题,可提高多模态筛查性能评估的准确性。
研究设计与样本
- 研究基于乳腺癌症监测联盟2005至2017年8260次筛查性乳腺X线摄影,配对±90天内的筛查MRI为联合筛查、91至270天为交替筛查;联合筛查3810对,交替筛查4450对;性能按各模态1年随访及将两检测视为单一检测的单一随访期计算,交替筛查另采用截断随访(若1年内再次筛查则随访止于下次筛查)。
诊断标准与关键数值
- 联合筛查3810对:单独乳腺X线癌检出率每1000次6.8(95%CI 4.6-10.0),单独MRI 12.3(95%CI 9.3-16.4),作为单一联合检测13.1(95%CI 10.0-17.3)。
- 联合筛查3810对:单独乳腺X线敏感度48.1%(35.0%-61.5%),单独MRI 79.7%(95%CI 67.7%-88.0%),作为单一联合检测96.2%(95%CI 85.9%-99.0%)。
- 交替筛查4450对:乳腺X线癌检出率每1000次由3.6(95%CI 2.2-5.9)变为截断随访下0,敏感度无法计算(分母=0)。
- 交替筛查4450对:MRI癌检出率每1000次由12.1(95%CI 9.3-15.8)变为截断随访下11.7(95%CI 8.9-15.3),敏感度由75.0%(95%CI 63.8%-83.6%)变为86.7%(95%CI 75.5%-93.2%)。
临床应用与阅片要点
- 评估多模态乳腺筛查性能时,应区分联合筛查与交替筛查的时序安排,并说明随访期如何界定。
- 联合筛查将乳腺X线与MRI视为单一检测计算性能,与分别计算各模态性能的结果不同。
- 交替筛查采用截断随访时,结局归因受重叠随访期影响,作者认为更新审计方法可提高多模态筛查性能评估的准确性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Mammography and MRI screening typically occur in combination or in alternating sequence. We compared multimodality screening performance accounting for the relative timing of mammography and MRI and overlapping follow-up periods.
METHODS: We identified 8,260 screening mammograms performed 2005 to 2017 in the Breast Cancer Surveillance Consortium, paired with screening MRIs within ±90 days (combined screening) or 91 to 270 days (alternating screening). Performance for combined screening (cancer detection rate [CDR] per 1,000 examinations and sensitivity) was calculated with 1-year follow-up for each modality, and with a single follow-up period treating the two tests as a single test. Alternating screening performance was calculated with 1-year follow-up for each modality and also with follow-up ending at the next screen if within 1 year (truncated follow-up).
RESULTS: For 3,810 combined screening pairs, CDR per 1,000 screens was 6.8 (95% confidence interval [CI]: 4.6-10.0) for mammography and 12.3 (95% CI: 9.3-16.4) for MRI as separate tests compared with 13.1 (95% CI: 10.0-17.3) as a single combined test. Sensitivity of each test was 48.1% (35.0%-61.5%) for mammography and 79.7% (95% CI: 67.7%-88.0%) for MRI compared with 96.2% (95% CI: 85.9%-99.0%) for combined screening. For 4,450 alternating screening pairs, mammography CDR per 1,000 screens changed from 3.6 (95% CI: 2.2-5.9) to zero with truncated follow-up; sensitivity was incalculable (denominator = 0). MRI CDR per 1,000 screens changed from 12.1 (95% CI 9.3-15.8) to 11.7 (95% CI: 8.9-15.3) with truncated follow-up; sensitivity changed from 75.0% (95% CI 63.8%-83.6%) to 86.7% (95% CI 75.5%-93.2%).
DISCUSSION: Updating auditing approaches to account for combined and alternating screening sequencing and to address outcome attribution issues arising from overlapping follow-up periods can improve the accuracy of multimodality screening performance evaluation.
引用
- Lee JM, Ichikawa LE, Kerlikowske K, et al. Relative Timing of Mammography and MRI for Breast Cancer Screening: Impact on Performance Evaluation. J Am Coll Radiol. 2024. PMID: 38969253. doi:10.1016/j.jacr.2024.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。